ID18416A - Inhibitor metaloprotease diheterosiklik - Google Patents

Inhibitor metaloprotease diheterosiklik

Info

Publication number
ID18416A
ID18416A IDP972993A ID972993A ID18416A ID 18416 A ID18416 A ID 18416A ID P972993 A IDP972993 A ID P972993A ID 972993 A ID972993 A ID 972993A ID 18416 A ID18416 A ID 18416A
Authority
ID
Indonesia
Prior art keywords
diheterosiclic
metaloprotease
inhibitors
metaloprotease inhibitors
diheterosiclic metaloprotease
Prior art date
Application number
IDP972993A
Other languages
English (en)
Indonesian (id)
Inventor
Pikul Stanislaw
De Biswanath
Almstead Neil Gregory
Mcdow-Dunham Kelly Lynn
Taiwo Yetunde Olabisi
Bradley Rimma Sandler
Cupps Thomas Lee
Natchus Michael Georges
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ID18416A publication Critical patent/ID18416A/id

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDP972993A 1996-08-28 1997-08-28 Inhibitor metaloprotease diheterosiklik ID18416A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2484696P 1996-08-28 1996-08-28

Publications (1)

Publication Number Publication Date
ID18416A true ID18416A (id) 1998-04-09

Family

ID=21822698

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP972993A ID18416A (id) 1996-08-28 1997-08-28 Inhibitor metaloprotease diheterosiklik

Country Status (25)

Country Link
US (2) US6121258A (no)
EP (1) EP0923561B1 (no)
JP (1) JP3347331B2 (no)
KR (1) KR20000035920A (no)
CN (1) CN1228772A (no)
AR (1) AR009457A1 (no)
AT (1) ATE226573T1 (no)
AU (1) AU734834B2 (no)
BR (1) BR9712085A (no)
CA (1) CA2263917A1 (no)
CO (1) CO4920240A1 (no)
CZ (1) CZ62699A3 (no)
DE (1) DE69716615T2 (no)
DK (1) DK0923561T3 (no)
HU (1) HUP0000210A3 (no)
ID (1) ID18416A (no)
IL (1) IL128664A (no)
NO (1) NO314934B1 (no)
NZ (1) NZ334254A (no)
PE (1) PE2599A1 (no)
PL (1) PL331795A1 (no)
SK (1) SK25799A3 (no)
TR (1) TR199900382T2 (no)
WO (1) WO1998008823A1 (no)
ZA (1) ZA977696B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ62899A3 (cs) * 1996-08-28 1999-07-14 The Procter & Gamble Company 1,3-Diheterocyklické metaloproteázové inhibitory
NZ503945A (en) 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
HUP0101176A3 (en) 1998-02-04 2002-06-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
SK18302000A3 (sk) 1998-06-03 2001-06-11 Gpi Nil Holdings, Inc. N-viazané sulfónamidy n-heterocyklických karboxylových kyselín a izosterov karboxylových kyselín, farmaceutický prostriedok s ich obsahom a ich použitie
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
AU6060299A (en) * 1998-09-30 2000-04-17 Procter & Gamble Company, The Method of treating hair loss using ketoamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
BR9915940A (pt) * 1998-12-02 2001-09-11 Pfizer Prod Inc Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
EP1147085B1 (en) 1999-01-27 2005-11-16 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
CN1349498A (zh) 1999-03-03 2002-05-15 宝洁公司 含有链烯基和炔基的金属蛋白酶抑制剂
MXPA01008857A (es) 1999-03-03 2002-07-02 Procter & Gamble Inhibidores de metaloproteasa dihetero sustituidos.
CA2400862A1 (en) 2000-02-21 2001-08-23 Noriko Mukai Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
MXPA03000043A (es) 2000-06-30 2003-10-15 Procter & Gamble Promocion de la salud en todo el cuerpo.
JP2005500270A (ja) * 2001-05-29 2005-01-06 ギルフォード ファーマシュウティカルズ インコーポレイテッド 手術の結果として発生した神経損傷を治療するための方法
CA2464727A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
AU2004240629B2 (en) * 2003-05-16 2010-02-25 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
JP2007513083A (ja) * 2003-11-10 2007-05-24 アンジオテック インターナショナル アーゲー 医療用移植片および繊維誘発剤
JP4777738B2 (ja) * 2004-10-14 2011-09-21 株式会社 資生堂 Adam活性阻害物質によるしわの防止または改善
JP2007119444A (ja) * 2005-09-29 2007-05-17 Shiseido Co Ltd Adam阻害剤によるしわの防止または改善

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
DE4011172A1 (de) * 1990-04-06 1991-10-10 Degussa Verbindungen zur bekaempfung von pflanzenkrankheiten
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
IL98681A (en) * 1991-06-30 1997-06-10 Yeda Rehovot And Dev Company L Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives
DE4127842A1 (de) * 1991-08-22 1993-02-25 Rhone Poulenc Rorer Gmbh 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
ATE150452T1 (de) * 1992-04-07 1997-04-15 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
AU4267293A (en) * 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
NZ288298A (en) * 1994-06-22 1998-12-23 British Biotech Pharm Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors
DK0821671T3 (da) * 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
ES2170884T5 (es) * 1995-11-13 2007-04-01 Sanofi-Aventis Deutschland Gmbh Acidos alfa-iminohidroxamicos y carboxilicos n-sustituidos, ciclicos y heterociclicos.
HUP9902092A3 (en) * 1995-12-08 2000-12-28 Agouron Pharmaceuticals Inc La Metalloproteinase inhibitor benzenesulfonamide derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer

Also Published As

Publication number Publication date
BR9712085A (pt) 2000-10-24
WO1998008823A1 (en) 1998-03-05
NO990759D0 (no) 1999-02-18
EP0923561B1 (en) 2002-10-23
EP0923561A1 (en) 1999-06-23
CN1228772A (zh) 1999-09-15
PL331795A1 (en) 1999-08-02
KR20000035920A (ko) 2000-06-26
US6121258A (en) 2000-09-19
AR009457A1 (es) 2000-04-26
ATE226573T1 (de) 2002-11-15
JP2000516953A (ja) 2000-12-19
HUP0000210A2 (hu) 2001-04-28
NZ334254A (en) 2000-11-24
AU734834B2 (en) 2001-06-21
TR199900382T2 (xx) 1999-05-21
SK25799A3 (en) 1999-12-10
CA2263917A1 (en) 1998-03-05
NO990759L (no) 1999-04-27
ZA977696B (en) 1998-02-23
NO314934B1 (no) 2003-06-16
DE69716615T2 (de) 2003-06-18
DE69716615D1 (de) 2002-11-28
PE2599A1 (es) 1999-03-03
DK0923561T3 (da) 2003-02-24
US6399598B1 (en) 2002-06-04
JP3347331B2 (ja) 2002-11-20
IL128664A (en) 2003-07-06
AU4153097A (en) 1998-03-19
IL128664A0 (en) 2000-01-31
CO4920240A1 (es) 2000-05-29
CZ62699A3 (cs) 1999-07-14
HUP0000210A3 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
ID19198A (id) Inhibitor metaloprotease heterosiklik
ID18416A (id) Inhibitor metaloprotease diheterosiklik
ID18141A (id) Inhibitor metaloprotease 1,3-diheterosiklik
FI963597A0 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
ATE334700T1 (de) Refluxinhibitoren
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
ID27574A (id) Inhibitor enzim
ATE268781T1 (de) Thrombininhibitoren
PT927183E (pt) Inibidores espirociclicos de metaloproteases
NO20003256D0 (no) ACE inhibitor-MMP inhibitor kombinasjoner
BR9707086A (pt) Inibidores de proteinase aspartila
DE69736109D1 (de) Differenzierungsinhibitor
DE69526475T2 (de) 5-Alphareduktase-Inhibitoren
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO983283D0 (no) Hydrokamsyre-baserte Kollagenase-inhibitorer
ATE282629T1 (de) Thrombininhibitoren
DE69523450T2 (de) Inhibitor
DE69720957T2 (de) Ace-hemmer
PT948483E (pt) Inibidores da farnesil-transferase
BR9610514A (pt) Inibidores cicloantihelmínticos
ID17400A (id) Inhibitor naaladase
ID19929A (id) Inhibitor naaladase